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Özet
Amaç: Motor-komplet spinal kord yaralanmasının (SKY) prostat hacmi (Vp), 
total prostat spesifik antijen (PSA), serbest PSA (sPSA), serbest/total PSA 
oranı (s/tPSA) ve PSA dansitesi (PSAD) üzerine etkilerini araştırmak. Gereç ve 
Yöntem: Yirmi-beş SKY hastası ve 32 yaş-uyumlu kontrol analize dahil edil-
di. Vp transrektal ultrason yardımı ile hesaplandı, PSA, sPSA, FSH, LH ve total 
ve serbest testosteron seviyeleri ölçüldü ve s/tPSA ve PSAD değerleri hesap-
landı. Bulgular: Ortalama hasta yaşı 44.26±6.9yıl idi. SKY grubunda ortala-
ma Vp, kontrol grubuna göre anlamlı derecede düşük iken (19.30±6.88mL ve 
26.96±8.79mL, p=0.001), her iki grubun serum PSA, FSH, LH, total ve serbest 
testosteron düzeyleri benzerdi (p>0.05). SKY grubunda sPSA ve s/tPSA oranı 
kontrole göre düşük (sırasıyla 0.16±0.096 ve 0.28±0.18, p<0.001; 0.20±0.18 
ve 0.28±0.13, p=0.002), PSAD ise daha yüksek olarak saptandı (0.056±0.027, 
0.043±0.035; p=0.014). Tartışma: Sonuçlarımıza göre SKY kontrollere göre 
hipofizer-gonadal akstan ve serum testosterondan bağımsız olarak daha dü-
şük Vp, sPSA ve s/tPSA değerlerine neden olmaktadır. sPSA ve PSAD ile ilgili 
sonuçlarımızın desteklenmesi gereklidir.
Anahtar Kelimeler
Spinal Kord; Prostat; Prostat-Spesifik Antijen
Abstract
Aim: To evaluate the effects of motor-complete spinal cord injury (SCI) on 
prostate volume (Vp), total prostate specific antigen (PSA), free PSA (fPSA), 
free-total PSA ratio (f/tPSA) and PSA density (PSAD). Material and Method: 
25 SCI patients and 32 age--matched outpatient able--bodied controls were 
included in the analysis. Vp was measured on transrectal ultrasound, PSA, 
fPSA, FSH, LH and total and free testosterone levels were obtained and f/
tPSA and PSAD were calculated for all patients. Results: Mean patient age 
was 44.26±6.9 years. Mean Vp of the SCI group was significantly lower than 
controls (19.30±6.88 vs 26.96±8.79, p=0.001) while mean serum PSA, FSH, 
LH, total and free testosterone of the two groups were similar (p>0.05). 
Mean fPSA and f/tPSA were significantly lower (0.16±0.096 vs 0.28±0.18, 
p<0.001 and 0.20±0.18 vs 0.28±0.13, p=0.002, respectively) and PSAD was 
higher (0.056±0.027 vs 0.043±0.035, p=0.014) than those of the controls.
Discussion: According to our findings, motor-complete SCI causes lower Vp, 
fPSA and f/tPSA than the controls, independent from pituitary-gonadal axis 
and serum testosterone without any significant impact on serum PSA. Our 
results regarding fPSA and PSAD need further confirmation.
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Çalışma Amerikan Üroloji Derneği’nin 2011 yıllık kongresinde poster olarak sunulmuştur. (Mayıs 2011, WashingtonDC, ABD)
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Introduction
The effects of spinal cord injury (SCI) on male genital anatomy 
and function  have been of interest during the last two decades 
which mainly involve fertility and sexual problems. As a result 
of improvements and refinements in surgery, urology and reha-
bilitation, a remarkable increase in the life expectancy of SCI 
patients has been achieved and SCI patients became vulnerable 
to the same risks of becoming an “aging male” as the able-
bodied population. Erectile dysfunction, infertility and voiding 
problems, benign prostatic hyperplasia (BPH) and prostate can-
cer (CaP) are among the common urologic diagnoses observed 
in this patient population [1].
Despite few studies reporting lower incidences of CaP in the SCI 
patients, others report respectable CaP rates and even more 
frequent high stage disease than able-bodied CaP patients [2-
5]. Today PSA is still the most frequently used tool in CaP diag-
nosis. Although there are numerous reports about the effects of 
SCI on PSA levels, the results are controversial and a conclusion 
is yet to be achieved [1,6-12]. Nevertheless, it seems logical to 
assume that the use of PSA in SCI patients may be different in 
some aspects, as numerous factors that can affect PSA levels 
are involved, i.e. urinary infections, intermittent or indwelling 
catheters, and possible changes in volume as well as the func-
tion of the prostate. Likewise there are also studies regarding 
Vp in SCI patients with various results, and a consensus is yet to 
be achieved [1,6,10-13].
F/t PSA  and PSAD are the two PSA derivatives used in conjunct 
with total serum PSA, in order to increase the sensitivity and 
specifity of serum PSA when serum PSA is in so called “gray 
zone”. To our knowledge, there are no data in the literature re-
garding fPSA, f/tPSA and PSAD levels in SCI patients. Therefore, 
we compared fPSA in order to evaluate the altered PSA kinetics 
in SCI patients as well as f/tPSA and PSAD in order to get a 
primary idea about the changes in PSA derivatives.
Effects of motor-complete SCI on PSA, fPSA, f/tPSA, PSAD and 
Vp were evaluated in this study, in comparison with able-bodied 
controls.
Material and Method
Male complete-motor SCI patients from a Rehabilitation Center 
and age matched able-bodied controls from outpatient urology 
unit of our institution were included in the study over a period 
of five months. Control group was formed among the patients 
applying with any urological complaints other than erectile dys-
function, infertility or lower urinary tract symptoms. Inclusion 
criteria were SCI for at least 18 months for the SCI group, and 
at least 30 years of age for all. Patients with acute urinary infec-
tions, diabetes mellitus, known neurological disorders, CaP and 
history of androgen or anti-androgen treatments and prostatic 
surgery were excluded. Informed consent was obtained from all 
of the patients and the study was carried out in accordance with 
the Helsinki Declaration (1975,1983).
A detailed medical history was obtained including the time from 
SCI  onset,  medications  used,  past  surgeries  and  co-morbid 
medical situations. A digital rectal examination was performed 
evaluating the size and morphology of the prostate. Laboratory 
tests included urine-analysis, serum PSA, fPSA, total testoster-
one (T), FSH and LH (Beckman Coulter DXI, Brea CA, USA), free 
testosterone (fT) (BIO-TEK 987, Ankara, Turkey). Vp was cal-
culated by transrectal ultrasound (TRUS) with 6.5MHz biplanar 
probe (Hitachi.EUB-420, Hitachi Medical Systems, Tokyo, Japan), 
using ellipsoid formula (0.52xwidthxlengthxdepth). PSAD and f/
tPSA were calculated by dividing serum PSA to Vp, and dividing 
fPSA by PSA, respectively. Level and severity of the SCI was 
determined by spinal MRI and scoring of the lesion according 
to the American Spinal Injury Association (ASIA) classification. 
ASIA A and B lesions were accepted to be complete motor le-
sions. Twenty-five patients who had a motor-complete SCI and 
32 controls were included in the analytical phase of the study.
Statistical calculations were made using the software SPSS13 
for Windows (SPSS Inc. Chicago, Il., USA). Normality of data 
distribution was tested with Shapiro-Wilk test. Continous vari-
ables were compared using Student’s t test and Mann-Whitney 
U tests, while multiple comparisons were made using Kruskal-
Wallis test. Categorical data were analyzed with chi-square test. 
P values lower than 0.05 were accepted to be significant.
Results
Records of 25 SCI and 32 control patients were analyzed. Mean 
age of all patients was 44.26±6.9 (31-60) years, and the mean 
age of the two groups were similar (p=0.55) (Table1). Median 
time from the onset of SCI was 42 (18-396) months. Of the 
SCI patients, 2 had cervical, 14 had thoracic and 9 had lumbar 
spinal lesions. As bladder management, 7 patients were able 
to void with triggered reflex voiding, while 9 patients were on 
clean intermittent catheterization and 9 used indwelling cath-
eters due to nursing needs.
Mean prostate volume of the patients with SCI was significantly 
lower than that of controls (p=0.001). Serum PSA of SCI pa-
tients was not significantly different from the controls, while 
their fPSA was significantly lower (p>0.05, p<0.001) (Table1). 
T, fT, FSH and LH values of the two groups were similar. Two 
Table 1. Characteristics of SCI patients and able-bodied controls.
SCI (n=25) Control (n=32) p
Age (Years) 44.88±7.48 43.78±6.94 0.55*
Vp (ml) 19.30±6.88 26.96±8.79 0.001*
PSA (ng/ml) 1.05±0.56 1.09±0.73 0.816†
fPSA (ng/ml) 0.16±0.096 0.28±0.18 <0.001†
f/tPSA 0.20±0.18 0.28±0.13 0.002†
PSAD 0.056±0.027 0.043±0.035 0.014†
T (ng/ml) 3.78±1.35 3.87±1.43 0.981†
fT (pg/ml) 9.27±4.26 9.30±3.74 0.917†
FSH (mIU/ml) 7.6±5.9 6.59±4.35 0.994†
LH (mIU/ml) 4.59±3.50 4.47±2.27 0.541†
* Independent samples T-test,  †Mann-Whitney U Test
Vp: Prostate volume, fPSA: Free PSA, f/tPSA: free to total PSA, PSAD: PSA density, T: Tes-
tosterone, fT: free testoeterone
Table 2. The relation between bladder management of SCI patients and PSA, 
fPSA levels.
n=25 RV (n=7) ICC (n=9) IC (n=9) p*
PSA (ng/ml) 1.15±0.52 0.84±0.40 1.19±0.70 0.458
fPSA (ng/ml) 0.21±0.14 0.14±0.072 0.13±0.06 0.291
* Kruskal Wallis test 
RV: Reflex voiding, ICC: Intermittent clean catheterization, IC: Indwelling Cath-
eter
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PSA derivatives, f/tPSA and PSAD of the two groups were com-
pared; f/t PSA ratio of the SCI group was lower than the controls 
(p=0.002) while the PSAD was significantly higher (p=0.014). 
Clean intermittent catheterization and use of indwelling cath-
eters had no effect on serum PSA and fPSA within the SCI group 
(Table2).
Among the SCI group, the level of the spinal cord lesion did not 
affect Vp, Vt, VS and any of the blood tests (p>0.05 for all).
Discussion
The effects of complete motor SCI on male reproductive system 
has been studied in various aspects in the literature, scoping 
mainly on structural and functional changes in the prostate, tes-
tis, seminal vesicles and penis. However, to our knowledge there 
is no study in the literature on patients with motor-complete 
spinal lesions only. Patients with only motor -complete SCI were 
included in our study regardless of the level of the lesion, as not 
only it was shown that the severity of the paralysis is related to 
the magnitude of the effect of SCI on Vp and PSA serum levels, 
but also completeness of the lesion is an independent factor 
affecting PSA and Vp in SCI patients [10-12]. 
Data regarding the levels and use of PSA for CaP diagnosis in 
SCI patients is debateful. There are studies reporting lower, 
similar and higher levels of PSA serum levels in SCI patients 
when compared to able-bodied controls, in which the diversity 
of the results may be due to factors like differences in patient 
age, time from SCI onset, lesion severity, bladder management 
used, etc. [1,6-12]. In our study, PSA of patients with complete 
motor SCI was not significantly different from the controls. This 
finding is consistent with tendency in the literature, as in major-
ity of the studies, serum PSA of SCI patients were found to be 
similar with the controls, although differences in seminal PSA 
levels were defined [1,4,8,9,11]. In the largest series present-
ed which consisted of 366 SCI patients and 371 age-matched 
controls, Pramudji et al [4] failed to demonstrate differences in 
PSA levels between SCI patients and controls and also in the 
age-stratified sub-groups. Similarly, Pannek et al [1] could not 
demonstrate a significant difference between PSA levels of 100 
SCI patients and 575 non injured men. In a more recent study 
however, Bartoletti et al [12] showed lower PSA levels in SCI 
cohort of their study including 113 SCI and 109 controls, and 
they claimed that age at SCI onset and completeness of the spi-
nal lesion are two independent factors which significantly affect 
PSA and prostate volume in SCI patients. Although the lower 
PSA levels in SCI patients is rationalized with the early age at 
onset of SCI in their patient population, the mean age at onset 
given for the entire cohort was not far from the one given by 
former study of Pannek et al (46.6 vs 39.9 yrs) who did not find 
a significant difference between PSA levels of SCI patients and 
controls. Therefore, a consensus regarding the effects of SCI on 
PSA is yet to be achieved, although no significant interactions 
were demonstrated in the majority of the studies.
The effects of SCI on Vp are investigated in various studies in 
the literature. The need for somatic and/or autonomic innerva-
tion together with androgenic stimulation for the growth, func-
tion and maintenance of the prostate was demonstrated in ani-
mal models [14-18]. Pelvic plexus denervation caused an overall 
decrease in cell height, unilateral sympathectomy caused unilat-
eral atrophy and decreased DNA and protein content, and lysis 
of efferent autonomic nerves to prostate caused loss of tissue 
configuration and vanishing of entire epithelium, all of which 
suggest a role for the nervous system in prostate morphology 
and function [15,16,18]. Demonstration of prostatic involution 
stimulated by Botox in both rat and human prostates further 
supports the role of nervous system in prostatic growth [17,19]. 
Studies on prostates of human SCI patients, however, reported 
conflicting results. Tendency in the literature is towards a lower 
Vp in SCI patients, although a few studies reporting similar Vp’s 
with controls are also present. In our study, mean Vp of the SCI 
patients was significantly lower than controls (19 vs 27ml), in 
accordance with the majority of the studies. Pannek et al [1] 
reported a numerical but not significant difference in Vp’s of SCI 
patients and controls, and Shim et al [11] reported similar Vp of 
SCI patients and controls in Korean men. One possible reason for 
this result may be that their SCI population was heterogeneous 
regarding the completeness of the lesion (41% complete, 59% 
incomplete for the former). It was shown in rats that unilateral 
denervation affects ipsilateral portion of the prostate, hence bi-
lateral denervation would have a larger, global impact on gland 
volume [15,16]. Similarly, in humans, Frisbie et al [10] reported 
lower Vp’s in severely paralyzed patients when compared to less 
severely paralyzed patients and able-bodied controls. Moreover, 
Bartoletti et al showed in a multivariate analysis that, complete-
ness of the lesion is an independent factor for Vp in SCI patients 
[12]. Other studies report lower Vp in SCI patients with different 
characteristics (Age, origin etc) [10,12,13]. Our SCI cohort being 
consisted entirely of patients with complete motor SCI’s was 
probably an important factor for demonstration of almost 35% 
reduction in Vp of SCI patients with a strong statistical signifi-
cance. To our knowledge, our study is the first one to investigate 
fPSA, f/tPSA and PSAD in SCI population. Although PSA of the 
SCI patients were similar with controls in our study, their mean 
Vp which is a major determinant of serum PSA, was significantly 
lower. In order to correct PSA levels for Vp, PSAD values were 
calculated. Mean PSAD of SCI patients was significantly higher 
than the controls, which indicated a higher amount of serum 
PSA per gram of prostate tissue. This was an interesting result 
which was supported by the previous findings of Alexandrino 
et al [9], who concluded that SCI affected seminal PSA levels 
negatively, without changing PSA serum levels; which can be 
explained by the simultaneous secretory dysfunction and struc-
tural deterioration of the prostate, of which, former decreasing 
seminal PSA levels, and latter increasing the PSA leak into the 
circulation.
Conclusions
Motor-complete SCI causes lower prostate volume, lower se-
rum free PSA and free-to-total PSA ratios when compared to 
controls. On the other hand, serum total PSA is not affected, 
although amount of PSA secreted by ml of prostate tissue in-
creased. These findings suggest that production, secretion and 
forms of PSA in circulation may be altered by SCI, and use of 
PSA in SCI patients in the exact same way as it is used in able-
bodied population may have to be questioned in larger prospec-
tive studies including higher number of patients.
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